Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01952249 · ClinicalTrials.gov registry record · Phase 1
A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
A Phase 1 study, sponsored by OncoMed Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01952249: Clinical Trial Phase 1 study, sponsored by OncoMed Pharmaceuticals.
NCT01952249 is a Phase 1 study that was terminated before completion, run by OncoMed Pharmaceuticals. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01952249, a Phase 1 study, was terminated before completion, sponsored by OncoMed Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a Phase 1b/2 study of paclitaxel plus demcizumab in subjects with platinum resistant ovarian, primary peritoneal or fallopian tube cancer.
Primary Outcome
The maximum tolerated dose (MTD) will be determined in patients treated with demcizumab in combination with weekly paclitaxel
Interventions
- DRUG Taxol
- DRUG Demcizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-08-05 |
| Est. Completion | 2016-07-12 |
| Phase | Phase 1 |
Why NCT01952249 stopped before completion
NCT01952249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which Taxol is the first listed.
NCT01952249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01952249 about?
NCT01952249 is a clinical study titled "A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian". This is a Phase 1b/2 study of paclitaxel plus demcizumab in subjects with platinum resistant ovarian, primary peritoneal or fallopian tube cancer.
What is the current status of trial NCT01952249?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-08-05. Estimated completion is 2016-07-12.
What interventions are being tested in trial NCT01952249?
The interventions under investigation include: Taxol (DRUG), Demcizumab (DRUG).
Who is sponsoring clinical trial NCT01952249?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01952249's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI